Yesterday's announcement that Erbitux and chemotherapy proved effective in boosting survival in a late-stage trial for head and neck cancer could lead to a big boost in income for ImClone and Bristol-Myers Squibb. One analyst pegged the value of an additional approval as a first-line therapy for head and neck cancer at $350 million in annual sales. One of the keys to a successful added indication, though, will come when Erbitux is compared to a combination of chemotherapy and radiation, which is the standard therapy today.
- read the report on Erbitux from The Boston Globe
Erbitux approved for head and neck cancers. Report
Analysts raise doubts on Erbitux ruling. Report
ImClone touts survival rate in Erbitux cancer trial. Report